Company Filing History:

8 out of 4,447

Eli Lilly and Company

Assembly Biosciences, Inc.

patents

where one patent can have more than one assignee

Years Active: 1997-2021

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11078170 - Cyclic sulfamide compounds and methods of using same (2021-08-03),

2. 10987360 - Hepatitis B core protein modulators (2021-04-27),

3. 10968211 - Hepatitis B core protein modulators (2021-04-06),

4. 10947224 - Hepatitis B core protein allosteric modulators (2021-03-16),

5. 10273228 - Hepatitis B viral assembly effectors (2019-04-30),

6. 10220034 - Hepatitis B viral assembly effectors (2019-03-05),

7. 10183936 - Hepatitis B core protein allosteric modulators (2019-01-22),

8. 9796722 - Hepatitis B viral assembly effectors (2017-10-24),

9. 7790744 - Cyclic peptide antifungal agents and process for preparation thereof (2010-09-07),

10. 7326731 - Muscarinic agonists (2008-02-05),

11. 6939946 - Ring modified cyclic peptide analogs (2005-09-06),

12. 6916784 - Cyclic peptide antifungal agents and process for preparation thereof (2005-07-12),

13. 6743777 - Cyclic peptide antifungal agents and process for preparation thereof (2004-06-01),

14. 6653281 - Ring modified cyclic peptide analogs (2003-11-25),

15. 6384013 - Cyclic peptide antifungal agents and process for preparation thereof (2002-05-07),

Title: The Innovations of William Wilson Turner, Jr.

Introduction

William Wilson Turner, Jr., a prominent inventor based in Bloomington, IN, has made significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 16 patents, his work focuses on developing novel compounds aimed at addressing critical health issues, particularly viral infections.

Latest Patents

Turner's latest innovations include groundbreaking patents related to cyclic sulfamide compounds. His first patent discloses these compounds and their pharmaceutical compositions, which serve as modulators of Hepatitis B (HBV) core protein. This advancement holds promise for new methods in treating Hepatitis B infections. Additionally, he has developed compounds with allosteric effector properties against Hepatitis B virus core protein, further enhancing the therapeutic strategies available for managing viral infections.

Career Highlights

Throughout his career, William Wilson Turner, Jr. has held key positions in esteemed organizations such as Eli Lilly and Company and Indiana University. His work in these institutions has allowed him to push the boundaries of medicinal research and contribute significantly to the scientific community.

Collaborations

Turner's collaborative efforts with colleagues like Lee Daniel Arnold and Hans Maag have been instrumental in the success of his projects. Together, they have tackled complex challenges in the realm of viral infection treatment, resulting in innovative solutions that could impact countless patients.

Conclusion

William Wilson Turner, Jr.'s dedication to innovation and his extensive background in medicinal chemistry underscore the importance of collaboration and research in developing effective treatments for diseases such as Hepatitis B. His 16 patents not only highlight his prowess as an inventor but also reflect his commitment to advancing healthcare through innovative solutions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com